IL-10 and IL-2R as combined predictors of intravenous immunoglobulin resistance in Kawasaki disease: a retrospective cohort study

IL-10 和 IL-2R 作为川崎病静脉注射免疫球蛋白抵抗的联合预测因子:一项回顾性队列研究

阅读:2

Abstract

OBJECTIVE: Intravenous immunoglobulin (IVIG) resistance in Kawasaki disease (KD) increases the risk of coronary artery lesions (CALs) and the need for additional therapies. Early identification remains a clinical challenge. This study evaluated the predictive value of interleukin (IL)-10 and IL-2 receptor (IL-2R) in detecting IVIG resistance. METHODS: We retrospectively analyzed 529 children with KD treated at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, from November 2019 to December 2024. Demographic and clinical characteristics, and laboratory data were compared between IVIG-responsive and IVIG-resistant groups. Multivariable logistic regression was used to identify independent predictors, and receiver operating characteristic (ROC) curves were used to assess predictive performance. RESULTS: Among 529 patients, 88 (16.6%) were IVIG-resistant and 441 (83.3%) were IVIG-responsive. Compared with IVIG-responsive patients, IVIG-resistant patients had significantly higher levels of IL-10 and IL-2R. Both remained independent predictors after adjustment for confounders. ROC analysis demonstrated high predictive accuracy for IL-2R (AUC = 0.825) and limited predictive value for IL-10 (AUC = 0.767). The combination of IL-10 and IL-2R moderately improved predictive accuracy, achieving a better balance between sensitivity and specificity (AUC = 0.834, sensitivity 77.10%, specificity 79.56%). Subgroup analysis revealed that IL-2R had limited predictive value in infants younger than 12 months. However, in patients aged 12 months or older, both IL-10 and IL-2R were significant risk factors for IVIG resistance. CONCLUSION: IL-2R is an independent predictor of IVIG resistance in KD in the age group more than 12 months, and IL-10 serves as a complementary marker, and their combined use slightly enhances predictive utility across most age groups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。